CMS Proposes 'RAPID' Pathway to Cut Medicare Coverage Time for Breakthrough Devices From 5 Years to 60 Days

For millions of older Americans, the hardest part of a devastating diagnosis isn't learning that no treatment exists—it's learning that a life-changing treatment does exist, but Medicare will not pay for it yet.[5]

Historically, when the FDA approves a breakthrough medical device—like a novel heart valve, a neurostimulator, or a new diagnostic implant—patients face a bureaucratic "valley of death." It can take up to five years for Medicare to agree to cover the cost, leaving the most vulnerable patients waiting for access to technology that is already sitting on hospital shelves.[5]

That waiting period is about to collapse. The Centers for Medicare & Medicaid Services (CMS) and the FDA have jointly proposed the RAPID (Regulatory Alignment for Predictable and Immediate Device) coverage pathway, a structural overhaul of how medical innovation reaches the bedside.[1][2]

Under the new framework, Medicare coverage for eligible breakthrough devices could begin as soon as 60 days after FDA market authorization, transforming a multi-year ordeal into a matter of weeks.[2][3]

The traditional delay stems from a fundamental disconnect between two massive federal agencies. The FDA evaluates whether a device is safe and effective for the general public. CMS, however, evaluates whether a device is "reasonable and necessary" specifically for the Medicare population, which often skews older and has more complex health needs.[5]

Because the two agencies historically worked sequentially, a manufacturer might spend years running a clinical trial to satisfy the FDA, only to find out after approval that CMS wanted different data. This often forced companies to run entirely new, duplicative trials just to secure reimbursement, stalling patient access indefinitely.[2][5]

RAPID changes the sequence. CMS will now join the FDA and the device manufacturer during the initial trial design phase, known as the Investigational Device Exemption (IDE) stage.[1][3]

By aligning their evidence expectations before the first patient is even enrolled, the agencies ensure the trial generates the exact clinical outcomes both regulators need simultaneously. The manufacturer runs one trial, and both agencies get their answers.[2][3]

The result is a synchronized finish line. When the FDA grants market authorization, CMS will issue a proposed National Coverage Determination (NCD) on the exact same day.[2][3]

Following a mandatory 30-day public comment period, a final coverage decision is targeted within 60 days for Class II devices and 90 days for Class III devices. The procedural notice for the pathway is currently undergoing its own 60-day public comment period.[1][3]

Not every device qualifies for this fast track. RAPID is strictly reserved for FDA-designated Breakthrough Devices that address an unmet medical need specifically in the Medicare population. Class II devices must also be participating in the FDA's Total Product Life Cycle Advisory Program (TAP).[2]

There is also a regulatory trade-off. While CMS is speeding up the coverage timeline, it is simultaneously repealing an older shortcut known as the New Technology Add-On Payment (NTAP) alternative pathway for breakthrough devices.[4][5]

Manufacturers will now have to definitively prove their device offers a "substantial clinical improvement" over existing treatments to qualify for those add-on payments. The upfront bar for clinical evidence is higher, but the reward is immediate, predictable national access.[4][5]

Questions remain about execution. Both agencies are taking on significant new collaborative workloads, and it is unclear if current staffing levels can support a high volume of RAPID candidates without slowing down the review of standard medical devices.[5]

For patients, however, the bureaucratic mechanics matter less than the outcome. When a breakthrough device is the only thing standing between decline and recovery, cutting the wait time from years to months is nothing short of life-saving.[5]